U.S. Retail REITs Stock News

Ultragenyx Pharmaceutical: Recent Move in Context Ultragenyx Pharmaceutical (RARE) has drawn fresh attention after its recent trading, with the stock closing at US$26.13. Investors are weighing this price against the company’s mixed return profile across the past year and the past 3 months. See our latest analysis for Ultragenyx Pharmaceutical. The recent move to US$26.13 comes after a 12.87% 1 month share price return and a 10.72% year to date share price return, set against a 27.38% 1 year...

Recent performance snapshot Spectrum Brands Holdings (SPB) has drawn attention after a mixed run in the stock, with a 7 day decline and a small drop in the latest session alongside positive returns over the month and past 3 months. Over longer periods, total return over the past year and past 3 years is positive, while the 5 year total return is slightly negative. This gives investors a mixed performance profile to weigh against the company’s fundamentals. See our latest analysis for Spectrum...

How BridgeBio Pharma stock has been trading BridgeBio Pharma (BBIO) has drawn investor attention after a strong 1 year total return of 93.54%. This contrasts with weaker recent trading, with the stock down 6.2% over the past month and 13.79% year to date. See our latest analysis for BridgeBio Pharma. The recent 1 day and 1 month share price declines sit against a much stronger backdrop, with a 1 year total shareholder return of 93.54% and a 3 year total shareholder return above 3x. This...

Earnings, buyback and dividend set the stage for Healthcare Realty Trust Healthcare Realty Trust (HR) reported first quarter 2026 results, showing lower revenue than a year earlier alongside a much smaller net loss, while also completing a share repurchase tranche and affirming its quarterly dividend. See our latest analysis for Healthcare Realty Trust. The recent 13.1% 30 day share price return and 18.1% 90 day share price return suggest momentum has picked up, while the 1 year total...

In April 2026, Penske Automotive Group reported first-quarter 2026 results showing sales of US$7,657.8 million and net income of US$234.5 million, while also completing a long-running share repurchase program totaling 30,958,382 shares for US$2.32 billion since its 2010 authorization. The combination of softer year-over-year earnings and the completion of a buyback that has retired almost two-fifths of its shares reshapes how investors may weigh Penske’s capital returns against its current...

FedEx (FDX) is back in focus after expanding its work with ServiceNow to plug FedEx Dataworks logistics intelligence directly into ServiceNow’s procurement and supply chain platforms, creating data driven supplier and workflow tools. See our latest analysis for FedEx. Despite a 6.8% decline in the 7 day share price return and a small pullback today to US$375.93, FedEx still shows a 5.3% 30 day share price return and a 75.3% 1 year total shareholder return, which suggests that recent momentum...

Compass Minerals International (CMP) has just released its fiscal second quarter results, providing fresh data on profitability, segment margins, balance sheet activity and labor stability at a key mine operation. See our latest analysis for Compass Minerals International. The latest earnings release, return to quarterly net income and progress on debt reduction have come alongside a sharp turn in momentum. This includes a 42.2% year to date share price return and 57.24% 1 year total...

CVS Health (CVS) delivered first quarter 2026 earnings that came in ahead of expectations across all segments. This prompted higher full year earnings guidance and fresh attention on its pharmacy, insurance and technology plans. See our latest analysis for CVS Health. The 1-month share price return of 11.68% and 90-day share price return of 11.50% suggest momentum has picked up around the recent earnings beat and raised guidance. The 1-year total shareholder return of 33.46% points to a...

In April 2026, Mirion Technologies reported first-quarter revenue of US$257.6 million, up from US$202.0 million a year earlier, but swung from a small net income to a net loss of US$3.4 million, while also reaffirming its full-year 2026 earnings guidance. A key detail for investors is that Mirion’s full-year revenue growth outlook of approximately 22%–24% includes anticipated benefits from foreign exchange movements and recent acquisitions, which helps explain management’s confidence...

In the past week, OUTFRONT Media Inc. reported first-quarter 2026 results showing sales of US$429.6 million versus US$390.7 million a year earlier and a swing to net income of US$19.1 million, while also declaring a quarterly dividend of US$0.30 per share payable on June 30, 2026. This combination of revenue growth, a return to profitability, and a maintained cash dividend highlights improving operating performance and management’s confidence in the company’s cash generation. We’ll now...

Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused licensing deals and pipeline additions. See our latest analysis for Madrigal Pharmaceuticals. The share price has been volatile, with a 30 day share price return of 4.49% and a 90 day share price return of 11.99%. Yet year to date it is down 9.94%, while the 1 year total shareholder return of...

Sana Biotechnology, Inc. recently drew attention with heavy pre-earnings options activity and elevated implied volatility, ahead of its first-quarter earnings release and its past May 12, 2026 presentation at the BofA Securities Healthcare Conference. Investors are closely watching how Sana’s engineered cell therapy pipeline, including its collaborations with Beam Therapeutics and Mayo Clinic, might feature in these updates. We’ll now examine how this heightened options activity ahead of...

Krystal Biotech recently reported first-quarter 2026 results, with net income rising to US$55.93 million and diluted EPS from continuing operations reaching US$1.83, and it also secured FDA approval for at-home use of Vyjuvek for dystrophic epidermolysis bullosa patients. These stronger earnings and expanded Vyjuvek administration options, alongside a high-profile appearance at the upcoming BofA Securities Health Care Conference, highlight how Krystal Biotech is pairing commercial progress...

Apollo Global Management (APO) has drawn attention after reporting record fee related earnings and crossing US$1 trillion in assets under management in the first quarter of 2026, alongside higher dividends and reaffirmed guidance. See our latest analysis for Apollo Global Management. The latest results and US$1 trillion AUM milestone come after a mixed price pattern, with a 21.29% 1 month share price return but a 12.84% decline year to date and a 2.58% 1 year total shareholder return. Recent...

In April 2026, Williams-Sonoma, Inc. launched its tenth brand, Dormify, a digital-first concept offering stylish, functional furnishings tailored to dorms and compact living spaces, supported by tools like customizable wish lists, design guidance, and curated checklists. The Dormify rollout also introduced a Pick-Up Near Campus™ program that uses Williams-Sonoma’s 450-plus store network and dedicated concierges to streamline delivery for students and small-space renters. Next, we’ll examine...

In the past quarter, EastGroup Properties reported first quarter 2026 earnings that came in well above prior expectations, prompting analysts to raise their forecasts and highlight stronger near-term growth prospects. This earnings surprise has renewed attention on how the company’s logistics-focused portfolio and development pipeline may support its longer-term investment case. With first quarter earnings outperforming expectations, we’ll now examine how this stronger near-term outlook...

In late April 2026, FTAI Aviation Ltd. reported first-quarter results showing revenue of US$830.70 million and net income of US$137.90 million, alongside an increased quarterly ordinary dividend of US$0.45 per share and an expanded revolving credit facility with total commitments of US$2.03 billion. By pairing stronger quarterly profitability with higher common and preferred dividends and substantially greater lending capacity, FTAI signaled confidence in its balance sheet flexibility and...

In recent days, MSC Industrial Direct reached a new 52-week high after analysts backed the company’s cost-cutting and pricing initiatives, despite a prior fiscal second-quarter earnings and revenue miss. An interesting angle is that this renewed analyst confidence came even as MSC Industrial announced the upcoming departure of its Senior Vice President and General Counsel, Neal Dongre, suggesting investors are prioritizing operational improvements over leadership changes. Next, we’ll...

In early May 2026, Life Time Group Holdings reported first-quarter results showing year-on-year increases in sales to US$767.57 million, total revenue to US$788.7 million, and net income to US$88.1 million, alongside higher earnings per share. The company also raised its full-year 2026 revenue and net income guidance, while continuing to open large-format clubs and repurchasing shares, underscoring how earnings growth, expansion, and capital allocation are moving together. We’ll now examine...

Quaker Chemical Corporation recently reported past first-quarter 2026 results, with sales of US$480.48 million and net income of US$19.67 million, both higher than a year earlier. The jump in basic and diluted earnings per share from continuing operations to US$1.13 suggests improving efficiency and stronger profitability across the business. With earnings per share improving materially year over year, we’ll now examine how this update reshapes Quaker Chemical’s investment narrative. Invest...

In the past week, Immunocore Holdings plc reported first-quarter 2026 results, with revenue of US$106.68 million and net income of US$12.97 million, alongside a Shelf Registration filing for up to US$76.48 million of ordinary shares related to its employee share plan. The company also released five-year overall survival data for KIMMTRAK in metastatic uveal melanoma, reinforcing the therapy’s clinical profile while Q1 earnings growth highlighted increasing commercial traction. Next, we’ll...

In recent months, RBC Bearings has been highlighted in multiple fund investor letters for past strong quarterly results supported by aerospace and defense demand, price increases, content gains, and improving aircraft production rates, alongside a record backlog that signals resilient order momentum. These fund commentaries, combined with expectations for year-over-year earnings and revenue growth in the March 2026 quarter, have reinforced investor focus on RBC Bearings’ record order book as...

Summit Therapeutics Inc. has already reported first-quarter 2026 results, with net loss widening to US$189.42 million and basic and diluted loss per share from continuing operations at US$0.24, compared with US$62.91 million and US$0.09 a year earlier. This sharp increase in quarterly losses may prompt investors to reassess how Summit’s spending and cash use align with its late-stage oncology pipeline. Next, we’ll examine how this much larger quarterly net loss shapes Summit’s existing...

Why Select Medical Holdings Is On Investors’ Radar Today Select Medical Holdings (SEM) has drawn fresh attention after recent share price moves and updated return figures, prompting investors to reassess how its hospital and rehabilitation footprint fits into their portfolios. See our latest analysis for Select Medical Holdings. At a share price of $16.44, SEM’s recent 90 day share price return of 4.78% and year to date share price return of 10.93% sit alongside a 1 year total shareholder...